Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the first patient enrolled at Yale School of Medicine [1][2] - The trial will assess the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy in reducing alcohol cravings and consumption [2] - The U.S. substance use disorder treatment market was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, highlighting significant market potential for effective AUD treatments [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Clinical Trial Details - Eligible participants for the trial include individuals aged 18 to 60, either heavy binge drinkers or those diagnosed with AUD, who express a desire to reduce or stop drinking [3] - The trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, with additional sites under evaluation [3]
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment